Ikarian Capital’s Voyager Therapeutics VYGR Stock Holding History

Ikarian Capital’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$186K	Hold	53,063	–	–	0.02%	141
2026 Q1	$205K	Hold	53,063	–	–	0.02%	140
2025 Q4	$209K	Sell	53,063 -2,703	-5%	-$12K	0.02%	153
2025 Q3	$260K	Hold	55,766	–	–	0.03%	146
2025 Q2	$173K	Hold	55,766	–	–	0.03%	117
2025 Q1	$188K	Hold	55,766	–	–	0.02%	140
2024 Q4	$316K	Sell	55,766 -91	-0.2%	-$587	0.04%	141
2024 Q3	$327K	Hold	55,857	–	–	0.05%	126
2024 Q2	$442K	Sell	55,857 -125,000	-69%	-$1.05M	0.08%	96
2024 Q1	$1.68M	Sell	180,857 -125,000	-41%	-$1.06M	0.18%	93
2023 Q4	$2.58M	Hold	305,857	–	–	0.24%	79
2023 Q3	$2.37M	Buy	305,857 +5,857	+2%	+$53.5K	0.29%	77
2023 Q2	$3.44M	Buy	+300,000	New	+$3.1M	0.55%	49

Other funds holding VYGR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ikarian Capital's VYGR Position: Q2 2026 in Review

Ikarian Capital held its Voyager Therapeutics (VYGR) position steady in Q2 2026 at 53,063 shares worth $186K. The position accounts for 0.02% of the portfolio, ranked #141.

Ikarian Capital first reported a position in VYGR in Q2 2023 and has held it in 13 quarters since. The position peaked at $3.44M in Q2 2023. 136 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

Ikarian Capital held 53,063 shares of Voyager Therapeutics worth $186K as of Q2 2026.
Ikarian Capital left its Voyager Therapeutics share count unchanged in Q2 2026.
Voyager Therapeutics made up 0.02% of Ikarian Capital's portfolio in Q2 2026, its #141 holding.
Ikarian Capital first reported a position in Voyager Therapeutics in Q2 2023 and has held it in 13 quarters since.
Ikarian Capital's Voyager Therapeutics position peaked at $3.44M in Q2 2023.
136 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.